Whether or not percutaneous closure of patent foramen ovale (PFO) can benefit patients with cryptogenic embolism more than medical therapy depends on the device used, asserts a paper published online ...
Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...
MIAMI, FL – A clinical trial that compared catheter-based PFO closure using an investigational device found that there was no significant reduction in ischemic and bleeding events compared to standard ...
- Patent Foramen Ovale (PFO) Closure Devices Market size is expected to rise by 2026 owing to increasing prevalence, escalating preferences for minimally-invasive, safety, technically feasible ...
Abbott Laboratories ABT recently launched its Amplatzer Talisman PFO Occlusion System in Europe. The Talisman device aims to treat patent foramen ovale (PFO) patients who have had a stroke and are at ...
Abbott Laboratories ABT recently received FDA approval for its Amplatzer Talisman PFO Occlusion System to treat patent foramen ovale (PFO) patients at risk of recurrent ischemic stroke. The ...
Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...
MIAMI, FL – OCTOBER 25, 2012 – A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results